We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Bruker (BRKR) Up 12.5% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Bruker (BRKR - Free Report) . Shares have added about 12.5% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Bruker due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Bruker Corporation before we dive into how investors and analysts have reacted as of late.
Bruker Q2 Earnings Beat, Revenues Miss Estimates
Bruker posted second-quarter 2026 adjusted earnings of 49 cents per share, up 53.1% year over year. The figure beat the Zacks Consensus Estimate of 38 cents by 28.9%.
Quarterly revenues rose 5.2% to $838.5 million but missed the Zacks Consensus Estimate of $853.57 million by 2.2%.
BSI Bookings Signal Better Demand
BSI revenues increased 4.7% year over year to $767.3 million, with organic growth of 2.3%. The segment’s order book rose 10% organically, driven by more than 50% growth in semiconductor orders and more than 20% growth in biopharma bookings.
Segment Mix Favors CALID and BEST
BioSpin revenues edged up 0.2% year over year to $195.7 million. CALID revenues rose 8.6% to $310.3 million, while Nano revenues increased 3.6% to $261.3 million.
BEST revenues climbed 11.9% to $74.2 million, with organic growth of 8.9%, net of intercompany eliminations.
Margins Expand on Cost Actions
Adjusted gross margin expanded 350 basis points year over year to 52.1%. Non-GAAP operating margin widened 510 bps to 14.1%, with adjusted operating income rising 64.6% to $118.5 million.
Bruker delivered about $30 million of cost savings in the quarter and remains on track for more than $140 million of annualized savings in 2026. GAAP results included a $134.9 million non-cash goodwill impairment charge, contributing to a GAAP operating loss of $65.3 million.
Bruker Updates 2026 Outlook
Bruker now expects 2026 revenues of $3.54-$3.57 billion, representing 3%-4% reported growth. Organic growth remains projected at 1%-2%, while the foreign-currency tailwind is now expected at 0.5%, down from 1.5%.
Adjusted earnings guidance remains $2.10-$2.15 per share, implying 15%-17% growth. The company still targets 250-300 bps of adjusted operating margin expansion. For the third quarter, management expects organic revenue to be roughly flat to slightly higher, with about $20 million of semiconductor revenue shifting into the fourth quarter.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted -24.1% due to these changes.
VGM Scores
Currently, Bruker has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Bruker has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Bruker (BRKR) Up 12.5% Since Last Earnings Report?
It has been about a month since the last earnings report for Bruker (BRKR - Free Report) . Shares have added about 12.5% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Bruker due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Bruker Corporation before we dive into how investors and analysts have reacted as of late.
Bruker Q2 Earnings Beat, Revenues Miss Estimates
Bruker posted second-quarter 2026 adjusted earnings of 49 cents per share, up 53.1% year over year. The figure beat the Zacks Consensus Estimate of 38 cents by 28.9%.
Quarterly revenues rose 5.2% to $838.5 million but missed the Zacks Consensus Estimate of $853.57 million by 2.2%.
BSI Bookings Signal Better Demand
BSI revenues increased 4.7% year over year to $767.3 million, with organic growth of 2.3%. The segment’s order book rose 10% organically, driven by more than 50% growth in semiconductor orders and more than 20% growth in biopharma bookings.
Segment Mix Favors CALID and BEST
BioSpin revenues edged up 0.2% year over year to $195.7 million. CALID revenues rose 8.6% to $310.3 million, while Nano revenues increased 3.6% to $261.3 million.
BEST revenues climbed 11.9% to $74.2 million, with organic growth of 8.9%, net of intercompany eliminations.
Margins Expand on Cost Actions
Adjusted gross margin expanded 350 basis points year over year to 52.1%. Non-GAAP operating margin widened 510 bps to 14.1%, with adjusted operating income rising 64.6% to $118.5 million.
Bruker delivered about $30 million of cost savings in the quarter and remains on track for more than $140 million of annualized savings in 2026. GAAP results included a $134.9 million non-cash goodwill impairment charge, contributing to a GAAP operating loss of $65.3 million.
Bruker Updates 2026 Outlook
Bruker now expects 2026 revenues of $3.54-$3.57 billion, representing 3%-4% reported growth. Organic growth remains projected at 1%-2%, while the foreign-currency tailwind is now expected at 0.5%, down from 1.5%.
Adjusted earnings guidance remains $2.10-$2.15 per share, implying 15%-17% growth. The company still targets 250-300 bps of adjusted operating margin expansion. For the third quarter, management expects organic revenue to be roughly flat to slightly higher, with about $20 million of semiconductor revenue shifting into the fourth quarter.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted -24.1% due to these changes.
VGM Scores
Currently, Bruker has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Bruker has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.